Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.

Cancer science - 1 May 2022

Chin Yoon Ming, Shibayama Tomoko, Chan Hiu Ting, Otaki Masumi, Hara Fumikata, Kobayashi Takayuki, Kobayashi Kokoro, Hosonaga Mari, Fukada Ippei, Inagaki Lina, Ono Makiko, Ito Yoshinori, Takahashi Shunji, Ohno Shinji, Ueno Takayuki, Nakamura Yusuke, Low Siew-Kee

Abstract excerpt

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) significantly improve progression-free survival and have become the standard therapy for estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer patients. Treatment surveillance by radiological imaging has some limitations in detection and repeated biopsy genomic profiling is not clinically feasible. Serial circulating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Mutation

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 35201661
DOI: 10.1111/cas.15304
PMCID: PMC9128178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.PMID 35201661Read ↗

Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.Semantic proximity Read ↗

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.Semantic proximity Read ↗

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.Semantic proximity Read ↗

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerSemantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast CancerSemantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Analysis of circulating tumor DNA to monitor metastatic breast cancer.Semantic proximity Read ↗

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read ↗

Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.